By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-225-2860


SEARCH JOBS

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).


Key Statistics


Email:
Ownership: Public

Web Site: Ariad
Employees:
Symbol: ARIA
 




Segment
Oncology





Company News
Ariad (ARIA)’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study 12/7/2016 11:40:02 AM
Struggling Ariad (ARIA) Finally Catches a Break, Shows Off Data From Brigatinib for Lung Cancer Trial 12/7/2016 6:21:35 AM
Ariad (ARIA) Announces Data Presentations At American Society of Hematology Meeting 12/6/2016 9:06:06 AM
Ariad (ARIA) Presents Updated Brigatinib Data With 18.4 Months Median Intracranial Progression Free Survival (PFS) In Alk+ NSCLC Patients With CNS Metastases At The World Conference On Lung Cancer 12/5/2016 9:45:18 AM
Ariad (ARIA) Announces FDA Full Approval And Label Update For Iclusig (Ponatinib) Based On Long-Term Efficacy And Safety Data From Phase 2 PACE Clinical Trial 11/29/2016 10:48:21 AM
Ariad (ARIA) Announces Data Presentations At The World Conference On Lung Cancer 11/17/2016 11:53:52 AM
Ariad (ARIA) Announces Launch Of Inaugural ALK+ Day During Lung Cancer Awareness Month 11/14/2016 11:33:54 AM
Ariad (ARIA) Reports Third Quarter 2016 Financial Results 11/7/2016 10:43:28 AM
Ariad (ARIA) Announces U.S. FDA Acceptance Of NDA Filing For Brigatinib 10/31/2016 11:55:45 AM
Ariad (ARIA) Announces Publication Of The Preclinical Profile Of Brigatinib In The Journal Clinical Cancer Research 10/26/2016 10:13:25 AM
12345678910...
//-->